Five Prime Therapeutics: Jefferies Global Healthcare Conference (Five Prime Therap) - Jun 6, 2014 - "FP-1039 Has The Ideal Product For FGFR1 Gene-Amplified Tumors"; "FP-1039 Phase 1 study in unselected solid tumors: No MTD identified, even at high doses, 17 of 39 (44%) patients with stable disease, Expected to combine safety with standard-of-care therapies" "
P1 data • Oncology
|